Phase 4 Gastro-oesophageal Reflux Disease Trial, Recruiting NCT06255886 Sponsor: Odense University Hospital Condition: Gastro-oesophageal Reflux Disease
Back to Gord

Phase 4 Gastro-oesophageal Reflux Disease Trial, Recruiting

NCT06255886
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Babies who have been diagnosed with gastroesophageal reflux disease (GERD), which is a condition where stomach contents come back up into the food pipe
  • Babies who were referred to the trial before their first birthday
  • Babies who are older than 1 month at the time treatment begins
  • Babies who have at least 3 reflux episodes per day on average
  • Babies who are also experiencing at least one of the following: crying for no clear reason, discomfort or fussiness, trouble gaining weight or losing weight, refusing the breast or bottle, pauses in breathing, or arching of the back

Who may not be able to join:

  • Babies who have been diagnosed with, or are suspected of having, a syndrome or genetic condition
  • Babies who were born with significant physical abnormalities (minor ones may be acceptable — confirm with trial site)
  • Babies who have had abdominal surgery
  • Babies who have a metabolic disease
  • Babies who have taken a proton pump inhibitor (a type of stomach acid medication) within the past week
  • Babies who have a known allergy to proton pump inhibitors (a type of stomach acid medication)
  • Babies who have a known allergy to cow's milk protein
  • Babies who are currently on a diet that excludes cow's milk

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Gitte Zachariassen, Professor, H.C Andersen Childrens Hospital, Odense University Hospital and Syddansk University (SDU)

Phone: +4521787136

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Odense University Hospital
Registry
ClinicalTrials.gov
Start date
27 October 2025
Est. completion
26 December 2026

Where this trial is recruiting

🇩🇰 Denmark

Primary endpoints

Change from baseline in reflux episodes in the fourth week of active treatment, compared to placebo

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov